Phosphodiesterase inhibition in heart failure

Handbook of Experimental Pharmacology

Volumn 204, Issue , 2011, Pages 237-249

  Movsesian, Matthew A ^a   Kukreja, Rakesh C ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cAMP; Cardiomyopathy; Cardioprotection; cGMP; Inotropy; PDE1; PDE3; PDE4; PDE5

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; PHOSPHODIESTERASE I INHIBITOR; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVD3; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG; PHOSPHODIESTERASE IV INHIBITOR;

ARTICLE; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; ENZYME ACTIVITY; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE; HEART PROTECTION; HUMAN; INOTROPISM; LONG TERM CARE; MITOCHONDRIAL PERMEABILITY; MORTALITY; NONHUMAN; PDE3A GENE; PDE3A1 GENE; PDE3A2 GENE; PDE3A3 GENE; PDE3B GENE; PRIORITY JOURNAL; SIDE EFFECT; SUDDEN DEATH; VASODILATATION; ANIMAL; ENZYMOLOGY; REVIEW;

ANIMALS; CYCLIC AMP; CYCLIC GMP; HEART FAILURE; HUMANS; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHODIESTERASE INHIBITORS;

EID: 79960895578     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-17969-3_10     Document Type: Article

References (67)

1. Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P (2005) Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 25:CD002230
2. Baim DS, McDowell AV, Cherniles J et al (1983) Evaluation of a new bipyridine inotropic agent -milrinone -in patients with severe congestive heart failure. N Engl J Med 309:748-756 (Pubitemid 13004282)
3. Bender AT (2007) Calmodulin-stimulated cyclic nucleotide phosphodiesterases. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, FL, pp 35-54
4. Beuckelmann DJ, Nabauer M, Erdmann E (1992) Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85:1046-1055
5. Bristow MR, Ginsburg R, Umans V et al (1986) Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59:297-309 (Pubitemid 17178124)
6. Choi YH, Ekholm D, Krall J et al (2001) Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3Aexpressed in vascular smooth-muscle myocytes.BiochemJ 353:41-50 (Pubitemid 32094598)
7. Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955
8. Das A, Xi L, Kukreja RC (2008) Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283:29572-29585
9. Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC (2009) ERK phosphorylation mediates sildenafilinduced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 296:H1236-H1243
10. Dieterle T, Meyer M, Gu Y et al (2005) Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res 67:678-688 (Pubitemid 41033363)
11. Ding B, Abe J, Wei H et al (2005a) Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111:2469-2476 (Pubitemid 40696135)
12. Ding B, Abe J, Wei H et al (2005b) A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA 102:14771-14776 (Pubitemid 41457131)
13. Dorn GW 2nd (2009) Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res 81:465-473
14. Drakos SG, Kanakakis JV, Nanas S et al (2009) Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. J Cardiovasc Pharmacol 53:157-161
15. Eizema K, Fechner H, Bezstarosti K et al (2000) Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation 101:2193-2199 (Pubitemid 30253049)
16. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111:1601-1610 (Pubitemid 40525159)
17. Frace AM, Mery PF, Fischmeister R, Hartzell HC (1993) Rate-limiting steps in the beta-adrenergic stimulation of cardiac calcium current. J Gen Physiol 101:337-353 (Pubitemid 23106910)
18. Francis SH, Corbin JD (2005) Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol 1:283-293
19. Garlid KD, Costa AD, Quinlan CL, Pierre SV, Dos Santos P (2009) Cardioprotective signaling to mitochondria. J Mol Cell Cardiol 46:858-866
20. Hambleton R, Krall J, Tikishvili E et al (2005) Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 280:39168-39174 (Pubitemid 41713868)
21. Han SJ, Vaccari S, Nedachi T et al (2006) Protein kinase B/Akt phosphorylation of PDE3A and its role in mammalian oocyte maturation. EMBO J 25:5716-5725 (Pubitemid 44967755)
22. Hassan MA, Ketat AF (2005) Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 5:10
23. He H, Meyer M, Martin JL et al (1999) Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility. Circulation 100:974-980 (Pubitemid 29407179)
24. Hoshijima M, Ikeda Y, Iwanaga Y et al (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8:864-871
25. Iwanaga Y, Hoshijima M, Gu Y et al (2004) Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 113:727-736 (Pubitemid 38544166)
26. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS (1985) Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 75:643-649 (Pubitemid 15142075)
27. Juhaszova M, Zorov DB, Kim SH et al (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535-1549 (Pubitemid 39071677)
28. Kass DA, Champion HC, Beavo JA (2007) Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101:1084-1095 (Pubitemid 350146434)
29. Kenan Y, Murata T, Shakur Y, Degerman E, Manganiello VC (2000) Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE3) isoforms. J Biol Chem 275:12331-12338 (Pubitemid 30237816)
30. Lehnart SE, Wehrens XH, Reiken S et al (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123:25-35 (Pubitemid 41414526)
31. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 75:530-535 (Pubitemid 47080966)
32. Lin CS, Chow S, Lau A, Tu R, Lue TF (2002) Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 14:15-24 (Pubitemid 34188626)
33. Liu Y, Sato T, ORourke B, Marban E (1998) Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 97:2463-2469 (Pubitemid 28278191)
34. Marx SO, Reiken S, Hisamatsu Y et al (2000) PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101:365-376
35. Meyer M, Belke DD, Trost SU et al (2004) A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation. FASEB J 18:1312-1314 (Pubitemid 39561587)
36. Miller CL, Oikawa M, Cai Y et al (2009) Role of Ca2+/calmodulin- stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 105:956-964
37. Minamisawa S, Hoshijima M, Chu G et al (1999) Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99:313-322 (Pubitemid 29519910)
38. Movsesian MA, Bristow MR (2005) Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol 68:25-48 (Pubitemid 43588862)
39. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC (1991) Sarcoplasmic reticulumassociated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 88:15-19
40. Movsesian M, Stehlik J, Vandeput F, Bristow MR (2009) Phosphodiesterase inhibition in heart failure. Heart Fail Rev 14:255-263
41. Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA (2008) Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther 326:380-387
42. Nagayama T, Hsu S, Zhang M et al (2009) Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53:207-215
43. Nagendran J, Archer SL, Soliman D et al (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238-248 (Pubitemid 47196559)
44. Nanas JN, Tsagalou EP, Kanakakis J et al (2004) Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest 125:1198-1204 (Pubitemid 38501329)
45. Nimer LR, Needleman DH, Hamilton SL, Krall J, Movsesian MA (1995) Effect of ryanodine on sarcoplasmic reticulum Ca2+ accumulation in nonfailing and failing human myocardium. Circulation 92:2504-2510
46. Ockaili R, Salloum F, Hawkins J, Kukreja RC (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283:H1263-H1269
47. Pokreisz P, Vandenwijngaert S, Bito V et al (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119:408-416
48. Reiken S, Gaburjakova M, Guatimosim S et al (2003) Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing heartsRole of phosphatases and response to isoproterenol. J Biol Chem 278:444-453 (Pubitemid 36043595)
49. Salloum F, Yin C, Xi L, Kukreja RC (2003) Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92:595-597 (Pubitemid 36417692)
50. Salloum FN, Abbate A, Das A et al (2008) Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 294: H1398-H1406 (Pubitemid 351468739)
51. Salloum FN, Chau VQ, Hoke NN et al (2009) Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation 120:S31-S36
52. Sculptoreanu A, Rotman E, Takahashi M, Scheuer T, Catterall WA (1993) Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc Natl Acad Sci USA 90:10135-10139 (Pubitemid 23328266)
53. Shakur Y, Takeda K, Kenan Y et al (2000) Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J Biol Chem 275:38749-38761 (Pubitemid 32009210)
54. Shimizu K, Shintani Y, Ding WG, Matsuura H, Bamba T (2002) Potentiation of slow component of delayed rectifier K(+) current by cGMP via two distinct mechanisms: inhibition of phosphodiesterase 3 and activation of protein kinase G. Br J Pharmacol 137:127-137 (Pubitemid 34983471)
55. Simmerman HK, Jones LR (1998) Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 78:921-947 (Pubitemid 28491945)
56. Sinoway LS, Maskin CS, Chadwick B, Forman R, Sonnenblick EH, Le Jemtel TH (1983) Longterm therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 2:327-331 (Pubitemid 13078799)
57. Suckau L, Fechner H, Chemaly E et al (2009) Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119:1241-1252
58. Takasago T, Imagawa T, Shigekawa M (1989) Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase. J Biochem (Tokyo) 106:872-877 (Pubitemid 19285912)
59. Takimoto E, Champion HC, Li M et al (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214-222 (Pubitemid 40321358)
60. Takimoto E, Belardi D, Tocchetti CG et al (2007) Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 115:2159-2167 (Pubitemid 46659068)
61. Uretsky BF, Generalovich T, Reddy PS, Spangenberg RB, Follansbee WP (1983) The acute hemodynamic effects of a new agent, MDL 17, 043, in the treatment of congestive heart failure. Circulation 67:823-828 (Pubitemid 13161461)
62. Vandecasteele G, Verde I, Rucker-Martin C, Donzeau-Gouge P, Fischmeister R (2001) Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. J Physiol 533:329-340 (Pubitemid 32519991)
63. Vandeput F, Wolda SL, Krall J et al (2007) Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem 282:32749-32757 (Pubitemid 350159317)
64. Vandeput F, Krall J, Ockaili R et al (2009) cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 330:884-891
65. Watanabe A, Arai M, Yamazaki M, Koitabashi N, Wuytack F, Kurabayashi M (2004) Phospholamban ablation by RNA interference increases Ca2+ uptake into rat cardiac myocyte sarcoplasmic reticulum. J Mol Cell Cardiol 37:691-698 (Pubitemid 39194561)
66. Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, Movsesian MA (2002) Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 277:38072-38078 (Pubitemid 35154659)
67. Yan C, Miller CL, Abe J (2007) Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 100:489-501 (Pubitemid 46673258)